Cytosorbents vs Utah Medical Products
Cytosorbents and Utah Medical Products are similar in size: $37.1m and $38.5m of revenue in their latest fiscal years. Cytosorbents grew faster (4.1% against -5.8%). Utah Medical Products kept more of each dollar of sales as profit: a net margin of 29.3% against -22.1%. Utah Medical Products carries less debt relative to equity (0.2% against 311.7%).
| Latest fiscal year | CytosorbentsCTSO, 2025 | Utah Medical ProductsUTMD, 2025 |
|---|---|---|
| Revenue | $37.1m | $38.5m |
| Revenue growth | 4.1% | -5.8% |
| Net income | −$8.2m | $11.3m |
| Operating margin | -39.8% | 29.6% |
| Net margin | -22.1% | 29.3% |
| Return on equity | -96.4% | 9.5% |
| Free cash flow | −$12.5m | $14.3m |
| Cash | $6.2m | $85.8m |
| Total debt | $18.4m | $225,000 |
| Debt to equity | 311.7% | 0.2% |
| Dividend per share | — | — |
| Dividend yield | — | 1.8% |
| Share buybacks | — | $8.4m |
| Employees | 129 | 140 |
| Market value | $276m | $223m |
| Price vs our value range | — | Below our value range |
| Moat score | 28 (Weak) | 100 (Strong) |
| Insider trades, 12 months | 10 buys, 0 sales | 0 buys, 0 sales |